Skip to main content
. 2023 Apr 27;14:1145441. doi: 10.3389/fimmu.2023.1145441

Figure 6.

Figure 6

Effect of Dec and Aza pretreated AML cells on the anti-tumor capacity of CD44v6 CAR-T in vitro and in vivo. (A, B) Dec (A) and Aza (B) pretreated AML cells for 3 days were then co-cultured with CD44v6 CAR-T at an E:T of 10:1 for 24 (h) Flow cytometric detected the percentage of dead cells in MV4-11, SKM-1, SKM-1-DNMT3A-SC2 and SKM-1-DNMT3A-SC3 cells (n≥4) pretreated with Dec or Aza alone, CD44v6 CAR-T alone, and Dec or Aza in combination with CD44v6 CAR-T. (C) Dec pretreated MV4-11 cell xenograft model. BALB/c-nu mice were subcutaneously injected with 5×106 MV4-11-firefly luciferase (Luc+ MV4-11) cells on day 0. Dec 1 mg/kg or 100 μl PBS were injected intraperitoneally on days 7, 8, 9, 14, 15 and 16. CD44v6 CAR-T cells (5 × 106), NT cells (5 × 106), or 200 μl PBS were intratumorally injected on day 10 and day 17. Tumor burden was analyzed by BLI on days7, 14, 21 and 28. (D, E) Graph (D) and BLI images (E) showing the progress of tumor burden at the indicated time point. Data are depicted as the mean ± SD. *p<.05; **p<.01; ***p<.001; ****p<.0001; ns, not significant.